pH-responsive magnetic cyclodextrin-liposome nanoplatforms for stabilization and targeted delivery of topotecan

Basit Öğe Kaydı
dc.contributor.authorTural, Bilsen
dc.contributor.authorErtas, Erdal
dc.contributor.authorKurucay, Ali
dc.contributor.authorAtes, Burhan
dc.contributor.authorTural, Servet
dc.date.accessioned2026-04-04T13:35:00Z
dc.date.available2026-04-04T13:35:00Z
dc.date.issued2026
dc.departmentİnönü Üniversitesi
dc.description.abstractTopotecan (TPT), a potent anticancer agent, suffers from rapid hydrolysis of its active lactone ring under physiological conditions, severely limiting its clinical efficacy. To address this challenge, we developed a novel pH-responsive, magnetic drug delivery system integrating (3-cyclodextrin-functionalized Fe3O4 nanoparticles (Fe3O4@(3-CD) and liposomes. Fe3O4@(3-CD nanoparticles were synthesized via chemical co-precipitation and then loaded with TPT via host-guest complexation. The resulting Fe3O4@(3-CD@TPT complexes were encapsulated into liposomes using the sonication method to increase drug stability, maintain the stable lactone form, and achieve controlled release. Characterization by Transmission Electron Microscopy (TEM), Dynamic Light Scattering (DLS), Fourier Transform Infrared Spectroscopy (FTIR), High-Performance Liquid Chromatography (HPLC), and Vibrating Sample Magnetometry (VSM) confirmed the successful formulation. In vitro drug release studies demonstrated a diffusion-controlled release profile, while the pH responsiveness of the system was primarily governed by pH-dependent drug stabilization and loading efficiency rather than pronounced differences in release kinetics. Cytotoxicity assays against MCF-7 breast cancer cells showed that the Fe3O4@(3CD@TPT@Liposome formulation exhibited significantly lower IC50 values compared to free TPT and Fe3O4@(3CD@TPT complexes. These results highlight the potential of the magnetic cyclodextrin-liposome hybrid platform as an effective strategy for the targeted and controlled delivery of pH-sensitive chemotherapeutics such as topotecan.
dc.description.sponsorshipDicle University Research Fund (DUBAP) [ZGEF.24.002, ZGEF.23.005, ZGEF.24.012, ZGEF.24.008, ZGEF.24.005]; TUBITAK 2211-C Domestic Priority Areas Doctoral Scholarship Program
dc.description.sponsorshipThis project is financially supported by the Dicle University Research Fund (DUBAP, Project No. ZGEF.24.002, Project No. ZGEF.23.005, Project No. ZGEF.24.012, Project No. ZGEF.24.008, Project No. ZGEF.24.005) . EE was supported by TUBITAK 2211-C Domestic Priority Areas Doctoral Scholarship Program.
dc.identifier.doi10.1016/j.jddst.2026.107976
dc.identifier.issn1773-2247
dc.identifier.issn2588-8943
dc.identifier.scopus2-s2.0-105026622608
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.jddst.2026.107976
dc.identifier.urihttps://hdl.handle.net/11616/109545
dc.identifier.volume116
dc.identifier.wosWOS:001660478400001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofJournal of Drug Delivery Science and Technology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectTopotecan
dc.subject(3-Cyclodextrin
dc.subjectMagnetic liposomes
dc.subjectControlled release
dc.subjectpH-responsive delivery
dc.subjectCancer therapy
dc.titlepH-responsive magnetic cyclodextrin-liposome nanoplatforms for stabilization and targeted delivery of topotecan
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu